A Message from Endo
To Our Valued Stakeholders:
Endo is working toward a business transformation that will put us in a stronger financial position for the future. On August 16, 2022, we initiated an in-court financial restructuring process after reaching an agreement with our senior debtholders on a transaction that would substantially reduce our debt and address opioid-related and other claims without the need for continued costly, time-consuming litigation.
We entered this process with ample liquidity to support our day-to-day operations, a portfolio of high-value products, and a demonstrated ability to bring innovative medications and new treatments to market. We are continuing to invest in and execute across our core areas of growth.
Our momentum and commitment to our mission, customers, patients, team members, and communities has not and will not change. We look forward to emerging from this process better positioned to continue helping everyone we serve live their best lives.
Above all, we are grateful for your ongoing support as we work to strengthen Endo for tomorrow.
Blaise Coleman
President & CEO
